Physician profile

Robert E Marx

Oral & Maxillofacial Surgery · Miami, FL

NPI 1922063122

$17,110.66

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$276.23

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lenkbar LLC $10,525.42 2021-2022
Medical Device Business Services, INC. $4,074.21 2019
Kls-Martin L.P. $1,280.74 2019-2024
Axogen $841.14 2020-2023 Avance Nerve Graft
Geistlich Pharma, North America, INC. $200.00 2022
Zimmer Biomet Holdings, INC. $139.37 2019
Ambu INC. $32.78 2020
Align Technology, INC. $17.00 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert E Marx

$17,110.66

in general payments reported 2019-2025

Years
2019-2024
Top company
Lenkbar LLC

https://glasscript.com/doctor/87414/robert-e-marx

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.